Expeditious, biologically driven Pilot Libraries for File Enhancement

描述(由申请人提供)：本申请的目的是通过分子图书馆筛选网络(MLSCN)产生中试规模的文库进行评估。预计MLSCN筛选这些“设计师收藏”的成果将有助于实现化学生物学的前景，发现高质量的小分子探针，以阐明未知功能的蛋白质的生理作用。将以25个文库为目标，包括25-80个特征化合物(&gt；10 mg，&gt；90%纯度)。为此，有效的文件增强需要多个功能领域的互补技能集，因此，集体研究人员提出了许多潜在的强大的医学相关方案，并在跨越学术和工业环境的高通量药物化学和药物设计原理方面拥有深厚的专业知识。协作方的综合基础设施进一步加强了这一应用，随时可以访问最先进的筛选、结构生物学、高通量仪器和核心化学设施。支架唯一性的概念将通过基于观察到的亚结构模式及其在PubChem和供应商数据库中出现的频率的分子相异度的测量来评估。评估工具将包括但不限于标准的不同子集和基于化学类型的分层分析。选定的支架也将具有很强的生物学合理性，通常利用多个靶标家族的关键分子识别基序。所有的脚手架都是独一无二的，在结构上都是引人注目的。再补给和未来的合成孔径雷达研究将通过选择具有“高迭代效率潜力”的支架来促进：1)提高药物化学家在“假设-合成-筛选”循环中的迭代速度；2)减少里程碑进展所需的迭代次数。在此详述的设计者文库将展示多种适应症治疗进展的机会。 公共卫生相关性：为改善人类健康和长寿创造了一个巨大的机会。现在可以通过制备这里详述的潜在分子探针的集合来研究过多的新大分子在疾病进展中的作用。一旦确定，这些小分子最终可能是解决目前未得到满足的医疗需求的疾病修饰药物的前体。

DESCRIPTION (provided by applicant): The aim of this application is to produce pilot-scale libraries for evaluation via the Molecular Library Screening Network (MLSCN). It is expected that the output from MLSCN screening of these "designer collections" will help enable the promise of chemical biology, unearthing quality small molecule probes to elucidate physiological roles of proteins of unknown function. 25 libraries will be targeted, comprising 25-80 characterized compounds (>10mg, >90% pure). To this end, effective file enhancement requires complementary skill sets in multiple functional areas and as such, the collective investigators have proposed a multitude of potentially robust medicinally relevant protocols and possess a depth of expertise in high-throughput medicinal chemistry and drug design principles spanning both academic and industrial settings. The combined infrastructures of the collaborative parties further strengthen this application, with ready access to state of the art screening, structural biology, high-throughput instrumentation and core chemistry facilities. The notion of scaffold uniqueness will be evaluated using measurements of molecular dissimilarity based on observed substructure patterns and their frequency of occurrence in PubChem and vendor databases. Evaluation tools will include but are not limited to standard diverse subset and hierarchical chemotype-based analyses. Selected scaffolds will also have a strong biological rational, often taking advantage of crucial molecular recognition motifs of multiple target families. All scaffolds are unique and viewed as structurally compelling. Resupply and future SAR studies will be facilitated by selection of scaffolds possessing 'High Iterative Efficiency Potential' that 1) improve the iterative speed of the medicinal chemist navigating the 'hypothesis-synthesis-screening' loop and 2) reduce the number of required iterations for milestone progression. Designer libraries detailed herein will be presenting opportunities for therapeutic advances in multiple indications. PUBLIC HEALTH RELEVANCE: An immense opportunity has been created to improve human health and longevity. Roles of a plethora of new macromolecules in disease progression may now be investigated by preparation of collections of potential molecular probes detailed herein. Once identified, these small molecules may ultimately be the precursors to disease modifying drugs that address currently unmet medical needs.